nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Aims+Scope/Editorial Board/Publication information
|
|
|
|
181 |
C |
p. |
artikel |
2 |
An ESTRO-ACROP guideline on quality assurance and medical physics commissioning of online MRI guided radiotherapy systems based on a consensus expert opinion
|
Tanadini-Lang, Stephanie |
|
|
181 |
C |
p. |
artikel |
3 |
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
|
Spampinato, Sofia |
|
|
181 |
C |
p. |
artikel |
4 |
Contents
|
|
|
|
181 |
C |
p. |
artikel |
5 |
Developing an AI-assisted planning pipeline for hippocampal avoidance whole brain radiotherapy
|
Lin, Chih-Yuan |
|
|
181 |
C |
p. |
artikel |
6 |
DKK1 affects survival of patients with head and neck squamous cell carcinoma by inducing resistance to radiotherapy and immunotherapy
|
Ye, Xinyu |
|
|
181 |
C |
p. |
artikel |
7 |
Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer – Results of a large multicenter analysis
|
Roesch, Johannes |
|
|
181 |
C |
p. |
artikel |
8 |
Dosimetric predictive factors for facial nerve paralysis after cyberknife® stereotactic radiotherapy for vestibular schwannomas: A single institution experience of 88 patients
|
Gehin, William |
|
|
181 |
C |
p. |
artikel |
9 |
Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis
|
Minniti, Giuseppe |
|
|
181 |
C |
p. |
artikel |
10 |
Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial
|
Cui, Tianxiang |
|
|
181 |
C |
p. |
artikel |
11 |
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial
|
Cooke, Saskia A. |
|
|
181 |
C |
p. |
artikel |
12 |
In regard to Yao et al.
|
Yuce Sari, Sezin |
|
|
181 |
C |
p. |
artikel |
13 |
In reply to the Letter to the Editor by Cengiz Beyan and Esin Beyan regarding ‘‘Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?”
|
Mao, Jing-Rong |
|
|
181 |
C |
p. |
artikel |
14 |
Overcoming inter-observer planning variability in target volume contouring and dose planning for high-risk neuroblastoma – a European multicenter effort of the SIOPEN radiotherapy committee
|
Jazmati, Danny |
|
|
181 |
C |
p. |
artikel |
15 |
Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis
|
Sidibe, Ingrid |
|
|
181 |
C |
p. |
artikel |
16 |
Response to the letter by Dr Sari regarding the article “The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy”
|
Yao, Ji-Jin |
|
|
181 |
C |
p. |
artikel |
17 |
RE: Venkatesulu et al. (Letter to the Editor)
|
Ellsworth, Susannah G. |
|
|
181 |
C |
p. |
artikel |
18 |
The prognosis may not be determined with the use of some pre-treatment complete blood count values in patients with non-metastatic nasopharyngeal carcinoma
|
Beyan, Cengiz |
|
|
181 |
C |
p. |
artikel |
19 |
Translational study for stereotactic body radiotherapy against non-small cell lung cancer, including oligometastases, considering cancer stem-like cells enable predicting clinical outcome from in vitro data
|
Saga, Ryo |
|
|
181 |
C |
p. |
artikel |
20 |
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion – Results from the 2SMART phase 2 trial
|
Ong, Wee Loon |
|
|
181 |
C |
p. |
artikel |
21 |
With regards to Ellsworth et al. on “Lymphocyte sparing normal tissue effects in the clinic LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy”
|
Venkatesulu, BhanuPrasad |
|
|
181 |
C |
p. |
artikel |